In The News: School of Integrated Health Sciences
In a new study from the Ê×Ò³| Â鶹´«Ã½Ó³», researchers confirmed the link between type 2 diabetes and Alzheimer’s disease.
Eisai and Biogen announced that Eisai has initiated a rolling submission to the US Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), the company’s investigational anti-amyloid beta (Aß) protofibril antibody, for the treatment of early Alzheimer’s disease (early AD).
Optimistic about the drug’s efficacy, the company has initiated its submission for accelerated FDA approval.
A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer's disease.
A team of neuroscientists at UNLV has reinforced the evidence for a link between type II diabetes and Alzheimer's disease.
A team of neuroscientists from the Ê×Ò³| Â鶹´«Ã½Ó³»-UNLV confirms the link between type II diabetes and Alzheimer's disease.
A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer's disease.
A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer’s disease.
A new program at UNLV is addressing a critical healthcare shortage in the Las Vegas valley.
Dr. Kara Radzak discusses recent updates in sport-related concussion assessment and rehabilitation with Dr. Abigail Bretzin, Dr. Jaclyn Caccese, and Dr. Justin Karr.
The occupational therapists in training at UNLV will one day work with people recovering from strokes, injury — and COVID-19.
Picture of UNLV School of Integrated Health Sciences students working on mobility training practices with infant dolls at the Occupational Therapy lab facility at the Shadow Lane campus.